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Mutations in profilin 1 (PFN1) are associated with amyotrophic lateral
sclerosis (ALS); however, the pathological mechanism of PFN1 in this
fatal disease is unknown. We demonstrate that ALS-linked mutations
severely destabilize the native conformation of PFN1 in vitro and
cause accelerated turnover of the PFN1 protein in cells. This mutation-
induced destabilization can account for the high propensity of ALS-
linked variants to aggregate and also provides rationale for their
reported loss-of-function phenotypes in cell-based assays. The source
of this destabilization is illuminated by the X-ray crystal structures of
several PFN1 proteins, revealing an expanded cavity near the protein
core of the destabilized M114T variant. In contrast, the E117G
mutation only modestly perturbs the structure and stability of PFN1,
an observation that reconciles the occurrence of this mutation in the
control population. These findings suggest that a destabilized form of
PFN1 underlies PFN1-mediated ALS pathogenesis.
amyotrophic lateral sclerosis | profilin 1 | protein stability | X-ray
crystallography | protein misfolding
Mutations in the profilin 1 gene (PFN1) were recently as-sociated with both familial and sporadic forms of amyo-
trophic lateral sclerosis (ALS) (1, 2), an incurable and fatal
neurodegenerative disease that primarily targets motor neurons
(3). The etiology of sporadic ALS is poorly understood, whereas
familial ALS is caused by inheritable genetic defects in defined
genes such as PFN1 (3). PFN1 is a 15-kDa protein that is best
known for its role in actin dynamics in the context of endocytosis,
membrane trafficking, cell motility, and neuronal growth and
differentiation (4). In addition to binding monomeric or G-actin,
PFN1 also binds to a host of different proteins through their poly-
L-proline motifs and to lipids such as phosphatidylinositol 4,5-
bisphosphate (4, 5). However, little is known about the mechanism(s)
associated with PFN1-mediated ALS pathogenesis. The observa-
tion that most ALS-linked PFN1 variants are highly prone to ag-
gregation in mammalian cultured cells suggests that disease-
causing mutations induce an altered, or misfolded, conformation
within PFN1 (2). Protein misfolding is a hallmark feature of most
neurodegenerative diseases, including ALS (3), and can contribute
to disease through both gain-of-toxic-function and loss-of-normal-
function mechanisms (6). Although mutations in PFN1 cause ALS
through a dominant inheritance mode (2), there is some evidence
supporting a loss-of-function mechanism for mutant PFN1. For
example, ALS-linked mutations were shown to abrogate the
binding of PFN1 to actin (2) and to impair the incorporation of
PFN1 into cytoplasmic stress granules during arsenite-induced
stress (7) in cultured cells. Moreover, ectopic expression of
these variants in murine motor neurons led to a reduction in
both axon outgrowth and growth cone size, consistent with a loss
of function through a dominant-negative mechanism (2).
Although ALS-linked mutations were shown to induce PFN1
aggregation, the effect of these mutations on protein stability
and structure has not been studied. Because the impact of dis-
ease-causing mutations on protein stability varies from protein to
protein (8–10), these parameters must be determined empirically.
Here, we demonstrate that certain familial ALS-linked mutations
severely destabilize PFN1 in vitro and cause faster turnover of the
protein in neuronal cells. To gain insight into the source of this
mutation-induced instability, the 3D crystal structures for three
PFN1 proteins, including the WT protein, were solved by X-ray
crystallography. We discovered that the M114T mutation created a
cleft that extended into the interior of PFN1. Further, we predict
that the most severely destabilizing C71G mutation also creates a
cavity near the core of the PFN1 protein, proximal to the cleft
formed by M114T. Experimental mutations that create enlarged
pockets or cavities are known to exert a destabilizing effect on the
protein’s native conformation (11), and there are several examples
of mutation-induced cavity formation occurring in nature and dis-
ease (12, 13). Interestingly, the variant predicted to be the least
pathogenic according to recent genetics studies, E117G, was rela-
tively stable and closely resembled the WT protein in every assess-
ment performed herein (2, 14). These data implicate a destabilized
form of PFN1 in ALS pathogenesis and call for therapeutic strate-
gies that can stabilize mutant PFN1.
Results
ALS-Linked Mutations Destabilize PFN1 in Vitro. To investigate the
effect of ALS-linked mutations on the stability of PFN1, PFN1
proteins were expressed and purified from Escherichia coli and
subjected to chemical and thermal denaturation analyses. A
novel purification protocol that includes sequential cation-
exchange and gel filtration chromatography steps was developed
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here and applied to all PFN1 variants (Materials and Methods).
PFN1 C71G was found to be highly prone to aggregation in
E. coli, consistent with observations that this variant exhibited
particularly low solubility in mammalian cells (2), and therefore
was isolated from inclusion bodies (Materials and Methods). The
biochemical properties of PFN1 C71G purified from inclusion
bodies are indistinguishable from PFN1 C71G purified from the
soluble lysate of E. coli as determined by several assays (Fig. S1),
providing confidence that PFN1 proteins purified by these two
methods can be directly compared.
To examine the stability of PFN1 proteins, fluorescence from
tryptophans (W4 and W32) in PFN1 WT and ALS-linked variants
was measured as a function of increasing urea concentration (Fig.
1A). To ensure reversibility, the reciprocal analysis was also per-
formed, where denatured PFN1 proteins in urea were refolded
upon dilution with buffer (Fig. S2 A–E). Only one transition was
observed between the folded or native (N) and unfolded (U) states
for all PFN1 proteins, indicative of a two-state (N$U) unfolding
mechanism. This two-state unfolding model was further sub-
stantiated with an unfolding study of two PFN1 proteins (WT and
M114T) using CD spectroscopy (Fig. S2F). The following thermo-
dynamic parameters were determined by fitting the fluorescence
data to a two-state folding model: apparent ΔG°, the free energy of
folding; m, the denaturant dependence of ΔG°; and Cm, the mid-
point of the unfolding transition (Table 1). Both ΔG° and Cm were
reduced for ALS-linked variants relative to PFN1 WT, particularly
for the PFN1 variants C71G, M114T, and G118V, indicating these
variants are severely destabilized compared with PFN1WT (Fig. 1A
and Table 1). Differential scanning fluorimetry (DSF) with SYPRO
Orange, a fluorescent indicator of hydrophobic regions exposed
upon protein unfolding, was used next to determine the apparent
melting temperature, Tm, for all PFN1 proteins used in this study
(15). Consistent with the chemical denaturation results, all ALS-
linked variants except E117G exhibited a Tm that was at least 10 °C
lower than WT (Fig. 1B and Table 1). Based on the denaturation
studies, C71G emerges as the most destabilizing mutation in the
context of PFN1, whereas the E117G mutation has a relatively
modest impact on PFN1 stability.
ALS-Linked PFN1 Exhibits Faster Turnover in a Neuronal Cell Line. The
turnover rate for proteins with destabilizing mutations is often
faster relative to their WT counterparts, generally because
destabilized proteins are misfolded and targeted for degradation
by the cellular quality control machinery (16). To determine
whether the results of our in vitro denaturation studies extend to
a cellular environment, V5-tagged PFN1 variants were tran-
siently transfected into human neuronal SKNAS cells, and PFN1
turnover was assessed by tracking V5-PFN1 protein expression
over a 12.5-h time course in the presence of cycloheximide. At
the start of the experiment (t = 0 of the cycloheximide time
course), all V5-tagged PFN1 variants were expressed at similar
levels except that V5-PFN1 C71G, M114T, and G118V parti-
tioned into the insoluble fraction (Fig. 2 A and B) as reported
previously (2). The turnover of both PFN1 C71G and M114T
occurred significantly faster than that of PFN1 WT. As early as
2.5 h, the majority of PFN1 C71G and M114T within the soluble
fraction had already degraded (Fig. 2 A and C). This decrease in
soluble PFN1 content was not simply due to further PFN1 ag-
gregation, which could confound our analysis, as evidenced by
the concomitant clearance of PFN1 from the insoluble fraction
at the early time points of cycloheximide exposure (Fig. 2B). The
faster turnover of PFN1 C71G and M114T in cells closely cor-
relates with their reduced stabilities in vitro, confirming the
destabilizing effect of the C71G and M114T mutations. We note
that the turnover of PFN1 C71G was faster in the soluble frac-
tion compared with the insoluble fraction (Fig. S3), likely be-
cause clearance of insoluble cellular aggregates by the quality
control machinery is less efficient compared with the turnover of
smaller, soluble species (17). Although PFN1 G118V was destabi-
lized to a similar degree as M114T in vitro, the turnover of this
variant within the soluble fraction seemed slower in cells (Fig. 2C),
which may reflect a stabilizing effect of other proteins and/or factors
that interact with PFN1 in the cellular milieu (4), or that this variant
is not properly handled by the quality control machinery in the cell.
In fact, we detected a low level of insoluble PFN1 G118V that
persisted throughout the 12.5-h time course (Fig. 2B and Fig. S3).
ALS-Linked Mutations Induce a Misfolded Conformation Within PFN1.
We reasoned that ALS-linked variants must undergo some de-
gree of structural or conformational change to account for their
destabilization. However, ALS-causing mutations did not perturb
Fig. 1. ALS-linked mutations destabilize PFN1. Chemical and thermal de-
naturation studies reveal that ALS-linked variants C71G, M114T, and G118V,
but not E117G, are severely destabilized relative to PFN1 WT. (A) Equilibrium
unfolding curves for PFN1 WT and ALS-linked variants generated by mea-
suring the intrinsic tryptophan fluorescence of the indicated protein equil-
ibrated in increasing concentrations of urea. Data were processed to obtain
the center of mass (COM) of the emission spectrum and then fit to a two-
state model for protein folding. The resulting fits are displayed as solid lines.
The corresponding thermodynamic parameters obtained from the fitted
data are shown in Table 1. (B) Thermal denaturation profiles of PFN1 pro-
teins measured by SYPRO Orange fluorescence as a function of increasing
temperature were used to determine the apparent Tm, which is the tem-
perature corresponding to 0.50 fluorescence signal as denoted by the in-
tersection of the dashed lines for each curve.
Table 1. Summary of experimental stability and binding measurements for PFN1 variants
Variant
Equilibrium unfolding (N$U)* Tm,
† °C
Binding to poly-L-proline†,‡
Kd, μMΔG°, kcal·mol–1 m, kcal·mol–1·M–1 Cm, M Protein alone + 4 mM proline
WT 7.04 ± 0.49 2.25 ± 0.16 3.13 ± 0.31 54.68 ± 0.04 57.25 ± 0.03 463 ± 26
C71G 1.89 ± 0.70 1.95 ± 0.40 0.97 ± 0.41 34.60 ± 0.03 39.96 ± 0.03 687 ± 77
M114T 3.51 ± 0.40 2.51 ± 0.24 1.40 ± 0.21 42.62 ± 0.03 46.52 ± 0.02 572 ± 23
E117G 6.90 ± 0.74 2.49 ± 0.26 2.77 ± 0.42 51.05 ± 0.04 53.78 ± 0.03 407 ± 27
G118V 3.70 ± 0.44 2.20 ± 0.23 1.68 ± 0.26 42.84 ± 0.04 46.92 ± 0.04 397 ± 40
*Errors are shown as SD.
†Errors are shown as SE.
‡Kd values are reported in terms of proline residues.
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the secondary structural elements of PFN1 as determined by CD
spectroscopy (Fig. S4), and the fact that similar m values were de-
termined for all PFN1 variants by the urea denaturation analysis
suggested these proteins adopt similar tertiary structures as well
(Table 1) (18). To probe further for potential structural differences
between PFN1 WT and ALS-linked variants, these proteins were
subjected to native gel electrophoresis, a biochemical technique
capable of detecting conformational differences between misfolded
variants and their WT counterparts (19). PFN1 WT and E117G
migrated predominately as single, distinct bands with similar mo-
bility, whereas multiple bands of slower mobility were observed for
PFN1 variants C71G, M114T, and G118V (Fig. S5A). The slower
mobility bands likely reflect the larger hydrodynamic volume due to
partial unfolding of these variants. In addition, PFN1 C71G,
M114T, and G118V produced relatively large-molecular-weight
species that were retained in the stacking gel and unable to elec-
trophorese through the separating native gel but were resolublized
under conditions used for the denaturing gel (Fig. S5A). Analytical
size-exclusion chromatography revealed that all PFN1 proteins
eluted as expected for soluble, monomeric PFN1 (Fig. S5 B–G).
However, despite equal loading of PFN1 proteins onto the ana-
lytical size-exclusion column, the peak area corresponding to
soluble monomer PFN1 is reduced for ALS-linked variants, par-
ticularly for the most aggregation-prone variant, C71G. These
data are consistent with a loss of soluble monomer PFN1 in the
form of insoluble species that cannot pass through the analytical
size-exclusion column filter.
A Source of Mutation-Induced Destabilization Revealed by X-Ray
Crystallography of PFN1. Crystal structures of PFN1 proteins
were determined to identify regions within mutant PFN1 that are
conformationally distinct from PFN1 WT at atomic resolution.
PFN1 WT, E117G, and M114T produced crystals that diffracted
at relatively high resolution (∼2.2 Å; Table S1). The 3D structure
of human PFN1 WT agrees well with previously determined
structures (20–22). PFN1 WT and E117G crystallized in the
same space group, C121, whereas M114T crystallized in the P6
space group, with two molecules (designated as chains A and B)
in the asymmetric unit (Table S1).
Residues 22–36, 46–52, 101–105, 112–120, and 125–128 within
PFN1 were used for Cα superimposition of the four molecules
(PFN1 WT, M114T chains A and B, and E117G). In agreement
with the biochemical analyses described above (Table 1 and Fig.
S4), the secondary and tertiary structures of all three PFN1
proteins, including chains A and B of M114T, are highly similar
(Fig. 3). Although the space groups for PFN1 WT and M114T
crystals were different, we calculated the double difference plots
between these and the other PFN1 structures to get a sense for
structural perturbations potentially induced by the ALS-linked
mutations. Double difference plots were constructed by calcu-
lating the distances between all of the Cα atoms in PFN1 WT
and an ALS-linked variant separately, and then plotting the
difference of the difference between PFN1 structures as de-
scribed previously (23). Virtually no structural deviations were
observed between PFN1 WT and E117G, whereas moderate
differences were detected between WT and M114T (Fig. S6).
Next we sought to determine whether these moderate struc-
tural changes between PFN1 WT and M114T mapped to regions
involved in PFN1 function, namely to residues that make contact
with actin (24–31) or poly-L-proline (21, 22, 24, 32, 33). The
ternary complex comprised of PFN1 WT, actin, and the poly-L-
proline peptide derived from vasodilator-stimulated phospho-
protein (VASP) (21) (PDB ID code 2PAV) is shown in Fig. 4.
Residues with the highest (0.3 Å or greater) average of absolute
double difference (Avg-Abs-DD) values between PFN1 WT and
M114T chain B (Fig. S6C) were mapped onto PFN1 WT (Fig.
S7). PFN1 M114T chain B was used for this and all subsequent
structural comparisons because chain B had lower B factors
compared with chain A (Fig. S8). Indeed, several PFN1 residues
that reportedly make contacts with actin (V119, H120, G122,
and K126) and poly-L-proline (W4, Y7, H134, and S138) also
have relatively high Avg-Abs-DD values (Fig. S7).
To assess whether these mutation-induced structural changes
are sufficient to alter the normal binding interactions of PFN1,
Fig. 2. ALS-linked PFN1 variants exhibit faster turnover in a neuronal cell
line. SKNAS cells transiently transfected with V5-PFN1 constructs were treated
with cycloheximide (CHX) for up to 12.5 h, during which time lysates were
collected and probed by Western analysis with a V5-specific antibody to assess
the rate of PFN1 turnover in cells. (A and B) A representative Western blot
analysis of soluble and insoluble fractions from cell lysates demonstrates a de-
crease in V5-PFN1 protein with time. GAPDH serves a loading control for the
soluble fraction. (C) Densitometry analysis ofA reveals that the turnover of PFN1
C71G and M114T is significantly faster than that of PFN1 WT. Statistical signif-
icance was determined using a two-way ANOVA followed by a Tukey’s post hoc
analysis (*P < 0.05, **P < 0.01, #P < 0.0001). Error bars represent SEM. WT and
E117G, n = 3; G118V, M114T and C71G, n = 4 independent experiments.
Fig. 3. Superimposition of the crystal structures for PFN1 WT, E117G, and
M114T. (A and B) The secondary and tertiary structures for PFN1 WT (green),
E117G (mustard), M114T chain A (pink), and B (red) are highly superimpos-
able. For each structure, sticks and spheres denote the side chains and van
der Waals radii, respectively, for residues at position 114 and 117. Residue
117 is located within a solvent-exposed flexible loop that has no discernible
secondary structure, whereas Met114 is located within a β-sheet toward the
interior of the protein. (B) A zoomed cartoon representation showing resi-
dues within 4 Å of residue 114. The side chains of these residues are in-
dicated as sticks with nitrogen, oxygen, and sulfur atoms indicated in blue,
red, and yellow, respectively. The van der Waals radii of the atoms com-
prising residue 114 are reduced upon mutation of methionine (green and
mustard structures) to threonine (red and pink structures).
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we first monitored changes in the intrinsic tryptophan fluorescence
of PFN1 as a function of poly-L-proline peptide concentration (Fig.
5A). Our results revealed that the effect of ALS-linked mutations
on the PFN1-poly-L-proline interaction was modest, because the
apparent dissociation constants (Kd) were within twofold for all
PFN1 proteins in this study (Table 1). In fact, excess concentrations
of poly-L-proline effectively stabilized all PFN1 proteins as de-
termined by DSF, with the largest increase in Tm observed upon
poly-L-proline peptide binding to C71G (Fig. 5B and Table 1). Next,
we measured the binding capacity of our PFN1 proteins for G-actin
by comparing their concentration-dependent abilities to suppress
spontaneous polymerization of pyrenyliodoacetamide‐labeled actin
monomers (34). This assay is based on the fact that PFN1 binds
G-actin and inhibits actin nucleation in the absence of formins (34).
As expected, increasing concentrations of recombinant PFN1 WT
reduced the rate of actin polymerization, whereas the H120E var-
iant that exhibits impaired binding to actin failed to suppress actin
polymerization to the same extent (Fig. 6). Of the four ALS-linked
variants, only G118V was defective in suppressing actin polymeri-
zation, which was most apparent at the highest concentration of
PFN1 used in this assay, although this effect did not reach statistical
significance (Fig. 6). These data argue against a general mechanism
for PFN1-mediated ALS pathogenesis that involves impaired direct
binding between PFN1 and either poly-L-proline or actin.
Importantly, the X-ray crystal structures reveal a possible
mechanism by which ALS-linked mutations destabilize PFN1.
Residues Thr90, Met114, and Gln18 contribute to the formation
of a surface exposed pocket that was detected using SiteMap
(Fig. 7). Mutation of methionine to threonine at position 114
increased the size of this pocket, thereby forming a cleft, because
the residues nearby failed to rearrange and compensate for the
loss of van der Waals contacts (Fig. 7B). This cleft is expected to
exert a destabilizing effect on the native conformation of PFN1
owing to this loss of van der Waals contacts and the reduced
hydrophobicity of the threonine side chain relative to that of
methionine (11). Moreover, hydrophobic residues that are oth-
erwise buried in the PFN1 WT structure were exposed by the
cleft in the PFN1 M114T structure (Fig. 7 and Fig. S9). To in-
vestigate the potential impact of the C71G mutation on PFN1
structure, the cysteine side chain of residue 71 was removed to
mimic a glycine amino acid in the PFN1 WT structure using
PyMOL. Interestingly, this mutation is predicted to form a void
in the core of the protein that partially overlaps with the cleft
observed in the PFN1 M114T crystal structure (Fig. 7B). Anal-
ysis using PyMOL and SiteMap suggest that, unlike the solvent-
accessible WT and the M114T pocket, the proposed C71G void
is buried within the core of the protein. Solvent-inaccessible
voids have a more destabilizing effect than solvent-exposed
cavities (11, 35), providing an explanation for why the C71G
mutation is more destabilizing than M114T (Fig. 1).
Discussion
Here we show that ALS-linked mutations severely destabilize (Fig.
1) and alter the native protein conformation (Fig. 3) of PFN1.
Changes in protein stability owing to disease-causing mutations,
whether these mutations stabilize or destabilize the protein, are
thought to play a pivotal role in various disease mechanisms (13).
In the context of ALS, disease-linked mutations destabilize Cu,
Zn-superoxide dismutase (SOD1) (9), but instead hyperstabilize
TAR DNA-binding protein 43 (TDP-43) (8, 10, 36). These find-
ings underscore the importance of defining the toxic properties of
disease-linked proteins, thereby directing the rational design of
therapeutic strategies against those offending proteins (3).
Our X-ray crystal structures of PFN1 proteins illuminate a
probable source of mutation-induced destabilization. An enlarged
surface pocket, or void, forms as a result of the M114T mutation
(Fig. 7). The destabilizing effect of similar voids has been dem-
onstrated using a systematic site-directed mutagenesis approach
with lysozyme and is thought to arise from a loss of hydrophobic
interactions (11, 35). Examples of mutation-induced cavity for-
mation and destabilization have also been observed in nature (13).
Interestingly, modeling the removal of the cysteine side chain at
position 71 creates an internal cavity that is predicted to partially
overlap the cleft formed by M114T, raising the intriguing possi-
bility that both mutations destabilize PFN1 through a common
mechanism that involves the loss of hydrophobic and van der
Waals contacts within the same region of PFN1 (Fig. 7). Because
Fig. 4. Structure of actin–PFN1–VASP peptide ternary complex with the
actin and poly-L-proline binding residues mapped on PFN1. The X-ray structure
of the PFN1 WT (gray)–actin (blue)–poly-L-proline peptide (gold) complex
(PDB ID code 2PAV) is shown. Residues reportedly involved in actin binding
(V61, K70, S72, V73, I74, R75, E83, R89, K91, P97, T98, N100, V119, H120,
G122, N125, K126, Y129, and E130) and poly-L-proline binding (W4, Y7, N10,
A13, S28, S30, W32, H134, S138, and Y140) are highlighted in blue and gold,
respectively. The sites of ALS-linked mutations investigated in this study are
highlighted and labeled in black with side chains displayed as black sticks.
Residues involved in actin or poly-L-proline binding that also exhibit Avg-
Abs-DD values of 0.3 Å or greater between PFN1 WT and M114T chain B
(W4, K126, and S138) are labeled in black (the remaining residues that fulfill
this criteria are shown in Fig. S7).
Fig. 5. ALS-linked PFN1 variants retain the ability to bind poly-L-proline.
(A) Binding of PFN1 to the poly-L-proline peptide was monitored by measuring
the intrinsic tryptophan fluorescence of the indicated PFN1 protein as a
function of increasing peptide concentration. The data points were fit using
a one-site total binding model in GraphPad Prism and the apparent disso-
ciation constants (Kd) obtained from the fit are shown in Table 1. Note that
the concentration of the peptide is reported in terms of [proline] because
the peptide stock is supplied as a mixture of poly-L-proline species (Materials
and Methods). (B) DSF was performed as described in Fig. 1B in the presence
(dashed lines) and absence (solid lines) of 4 mM proline. The presence of
proline increases the Tm for all PFN1 proteins used in this study (Table 1), as
illustrated here for WT, C71G, and M114T.
Boopathy et al. PNAS | June 30, 2015 | vol. 112 | no. 26 | 7987
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G118V is located within a solvent-exposed flexible loop, it is dif-
ficult to predict whether this mutation propagates structural
changes to the same region affected by M114T. We note that the
phi and psi angles for Gly118 are in a region of the Ramachandran
plot that are generally disallowed for a valine residue, and therefore
we speculate that the G118V mutation also induces a conforma-
tional change within PFN1 that allows valine to adapt dihedral
angles that are energetically more favorable.
Our study also provides insight into the relative pathogenicity
of ALS-linked PFN1 variants. The pathogenicity of the E117G
variant was called into question after it had been detected in the
control population (2, 14, 37, 38). Moreover, this variant exhibited
mild phenotypes compared with other ALS-linked PFN1 variants in
cell-based functional experiments (2, 7). Here, the E117G mutation
had only a modest effect on the stability and structure of PFN1
(Table 1 and Fig. S6), supporting the view that E117G is a risk
factor for disease rather than overtly pathogenic (1, 14). Further,
the E117G mutation was detected in sporadic ALS and fronto-
temporal lobar degeneration cases (14, 37–40), consistent with the
idea that environmental factors and/or genetic modifiers contribute
to PFN1 E117G toxicity. In fact, proteasome inhibition triggered
the aggregation of PFN1 E117G (2), suggesting that cellular stress
may exacerbate PFN1 misfolding and dysfunction in vivo.
Although the mechanism of PFN1 in ALS has yet to be fully
elucidated, the destabilized mutant-PFN1 species identified here
can serve as an upstream trigger for either loss-of-function or gain-
of-toxic-function mechanisms. Several investigations from cell-based
experiments support a loss-of-function mechanism for ALS-linked
PFN1 variants with respect to actin binding (2), actin dynamics (2),
and stress granule assembly (7). For example, PFN1 variants immu-
noprecipitated less actin from mammalian cells compared with PFN1
WT (2). Our in vitro results suggest this is unlikely due to a general
defect in the inherent ability of mutant PFN1 to directly bind actin
(Fig. 6) but may be the consequence of mutant PFN1 being se-
questered away from actin and/or engaged in other aberrant in-
teractions within the cell. Moreover, ALS-linked mutations do not
simply abrogate the direct-binding interaction between PFN1 and
the poly-L-proline motif (Fig. 5A) that is present in many biological
PFN1 ligands. These data, however, do not rule out the possibility
that mutation-induced misfolding and destabilization culminate in
defective actin homeostasis in vivo. PFN1 plays a complex role in
actin homeostasis, requiring coordinated interactions between PFN1
and many other cellular factors that ultimately dictate the fate of
different actin networks within the cell (41).
The misfolding of PFN1 variants may also induce gain of toxic
functions and interactions, the latter via aberrant protein–pro-
tein interactions through exposed hydrophobic patches, such as
those detected for PFN1 M114T (Fig. S9). Further, the aggregation
of PFN1 variants can potentially sequester other vital proteins, in-
cluding those with poly-L-proline binding motifs (4), culminating in
compromised actin and/or cellular homeostasis (6).
Although the downstream effect of ALS-linked PFN1 on actin
dynamics and other cellular processes have not been elucidated,
our data identify misfolded and destabilized PFN1 as a potential
upstream trigger of the adverse events that culminate in ALS,
opening new avenues for therapeutic advancement in ALS.
One potential direction is the development of pharmacological
chaperones (16). For example, small molecules that fill the void
formed by the M114T mutation are expected to stabilize the
protein (35). Our data with poly-L-proline (Fig. 5B) suggest that
small-molecules binding to other regions of PFN1 could also
stabilize the protein. We posit that stabilizing mutant PFN1 will
restore the normal structure and function of the protein, thereby
preventing the pathogenic cascade leading to ALS.
Materials and Methods
A pET vector containing human PFN1 flanked by NdeI and EcoRI restriction
sites was kindly provided by Bruce Goode, Brandeis University, Waltham,MA.
The mutant PFN1 DNA (2) was amplified using primers 5′- GGACCA-
TATGGCCGGGTGGAAC -3′ and 5′- GCCTGAATTCTCAGTACTGGGAACGC -3′
and ligated into the pET vector using NdeI and EcoRI restriction sites. BL21
(DE3) pLysS cells (200132; Agilent Technologies) transformed with PFN1
constructs were cultured in LB containing 100 μg·mL–1 ampicillin and
34 μg·mL–1 chloramphenicol at 37 °C until an OD600 of 0.7, at which point PFN1
expression was induced by addition of 1 mM isopropyl β-D-thiogalactopy-
ranoside (0487; Amresco) for either 3 h at 37 °C (for WT and E117G) or 24 h at
18 °C (for C71G, M114T, and G118V). Cells were harvested by centrifugation
and stored until purification. Refer to Supporting Information for complete
details on methods.
Fig. 7. The M114T mutation causes a surface-exposed pocket to expand
into the core of the PFN1 protein. (A) Residues are depicted as described in
Fig. 3. The van der Waals radii of residues 90, 114, and 18 are in contact in
the PFN1 WT structure (Top). These contacts are reduced by the M114T
mutation (Bottom) owing to the smaller size of threonine, leading to an
enlargement of the surface-exposed pocket. (B) PFN1 WT is shown with a
transparent surface and the secondary structure is shown in cartoon repre-
sentation. The surface pocket volume for PFN1 WT (green) and the cleft volume
for PFN1 M114T chain B (red) are depicted as opaque surfaces and were gen-
erated using SiteMap. The predicted cavity (blue) for PFN1 C71G (generated
using PyMOL) overlays with the M114T void, and unlike the WT and M114T
volumes, is not surface-exposed. The insets (Right) show the aforementioned
voids for WT (Top), M114T chain B (Middle), and C71G (Bottom).
Fig. 6. The binding of PFN1 proteins to G-actin. Polymerization of mono-
meric rabbit muscle actin (3 μM, 5% pyrene-labeled) was monitored in the
presence of increasing concentrations of WT or ALS-linked PFN1 variants and
used to derive relative rates of polymerization (n = 3). The variant H120E,
which is impaired in binding to actin, fails to suppress spontaneous actin po-
lymerization as effectively as WT PFN1. Although G118V is relatively weak in
suppressing actin polymerization, the data did not reach statistical signifi-
cance. Statistical significance was determined using a two-way ANOVA fol-
lowed by a Tukey’s post hoc analysis. **P ≤ 0.01 for WT vs. H120E at 7 μM
concentration. No other significant comparisons with WT were obtained.
Other significant comparisons included C71G vs. H120E and E117G vs. H120E
(P ≤ 0.05) at 7 μM concentration. Error bars represent SD.
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